- Report
- January 2025
- 100 Pages
Global
From €5638EUR$5,950USD£4,758GBP
- Report
- October 2024
- 198 Pages
Global
From €3359EUR$3,545USD£2,835GBP
€3733EUR$3,939USD£3,150GBP
- Report
- March 2025
- 92 Pages
Global
From €5307EUR$5,600USD£4,478GBP
- Report
- March 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,319GBP
Diastat is a brand of central nervous system (CNS) drugs used to treat seizures. It is a form of diazepam, a benzodiazepine, and is administered rectally. Diastat is used to treat acute repetitive seizures, also known as status epilepticus, in patients aged 6 months and older. It is also used to treat cluster seizures in patients aged 5 years and older. Diastat is available in a variety of forms, including a gel, a liquid, and a rectal suppository.
The Diastat market is a subset of the larger CNS drugs market. CNS drugs are used to treat a variety of neurological conditions, including epilepsy, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The Diastat market is highly competitive, with a number of companies offering similar products.
Some of the companies in the Diastat market include Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, and Actavis. Show Less Read more
